Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with Septerna to put new discovery-stage programs into play.

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter half of 2024 and has been underperforming since. The latest executive order on drug prices by President Donald Trump has only added to its woes, or has it?

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments for rights to preclinical oral small molecules that hit targets including GLP-1.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight loss treatments.

We recently published a list of 13 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks on Jim Cramer’s radar recently.

Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on NVO stock.

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as effective as a daily shot of Norditropin (somatropin) in children born small for gestational age (SGA), Noonan syndrome (NS), or with idiopathic short stature (ISS).

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo Nordisk's share is decreasing.